Antiplatelet therapy: Current strategies and future trends

Udaya S. Tantry, Amena Etherington, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Pharmacological management of thrombotic complications is strongly influenced by antiplatelet treatment strategies. Recent clinical trials have clearly indicated that current antiplatelet strategies may not inhibit recurrent thrombotic events in selected patients and improvement is necessary. Recently, there has been a gradual modification in the guidelines for clopidogrel dosing. In addition, newly developed P2Y12 receptor inhibitors and thrombin inhibitors are undergoing Phase II and III clinical trials. Moreover, research related to novel agents that interfere with other steps in coagulation and platelet adhesion, and platelet thromboxane and thrombin receptor blockers, show promise. An important future step will probably be the development of personalized therapy based on defining the individual patient's propensity for thrombosis through investigation of platelet-thrombin-fibrin interactions. Such an approach will enhance the targeting of specific therapy based on the pathophysiology of the individual patient.

Original languageEnglish (US)
Pages (from-to)343-366
Number of pages24
JournalFuture Cardiology
Volume2
Issue number3
DOIs
StatePublished - May 2006

Fingerprint

Thrombin Receptors
Blood Platelets
clopidogrel
Thromboxane Receptors
Phase III Clinical Trials
Phase II Clinical Trials
Fibrin
Thrombin
Thrombosis
Therapeutics
Clinical Trials
Pharmacology
Guidelines
Research

Keywords

  • Antiplatelet agents
  • Aspirin
  • GP IIb/IIIa inhibitors
  • P2Y receptor blockers
  • Platelet-thrombin-fibrin interaction
  • Thrombin inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Tantry, U. S., Etherington, A., Bliden, K. P., & Gurbel, P. A. (2006). Antiplatelet therapy: Current strategies and future trends. Future Cardiology, 2(3), 343-366. https://doi.org/10.2217/14796678.2.3.343

Antiplatelet therapy : Current strategies and future trends. / Tantry, Udaya S.; Etherington, Amena; Bliden, Kevin P.; Gurbel, Paul A.

In: Future Cardiology, Vol. 2, No. 3, 05.2006, p. 343-366.

Research output: Contribution to journalArticle

Tantry, US, Etherington, A, Bliden, KP & Gurbel, PA 2006, 'Antiplatelet therapy: Current strategies and future trends', Future Cardiology, vol. 2, no. 3, pp. 343-366. https://doi.org/10.2217/14796678.2.3.343
Tantry, Udaya S. ; Etherington, Amena ; Bliden, Kevin P. ; Gurbel, Paul A. / Antiplatelet therapy : Current strategies and future trends. In: Future Cardiology. 2006 ; Vol. 2, No. 3. pp. 343-366.
@article{d8a4c52cbae940288ebb06b6ce2aa6ed,
title = "Antiplatelet therapy: Current strategies and future trends",
abstract = "Pharmacological management of thrombotic complications is strongly influenced by antiplatelet treatment strategies. Recent clinical trials have clearly indicated that current antiplatelet strategies may not inhibit recurrent thrombotic events in selected patients and improvement is necessary. Recently, there has been a gradual modification in the guidelines for clopidogrel dosing. In addition, newly developed P2Y12 receptor inhibitors and thrombin inhibitors are undergoing Phase II and III clinical trials. Moreover, research related to novel agents that interfere with other steps in coagulation and platelet adhesion, and platelet thromboxane and thrombin receptor blockers, show promise. An important future step will probably be the development of personalized therapy based on defining the individual patient's propensity for thrombosis through investigation of platelet-thrombin-fibrin interactions. Such an approach will enhance the targeting of specific therapy based on the pathophysiology of the individual patient.",
keywords = "Antiplatelet agents, Aspirin, GP IIb/IIIa inhibitors, P2Y receptor blockers, Platelet-thrombin-fibrin interaction, Thrombin inhibitors",
author = "Tantry, {Udaya S.} and Amena Etherington and Bliden, {Kevin P.} and Gurbel, {Paul A.}",
year = "2006",
month = "5",
doi = "10.2217/14796678.2.3.343",
language = "English (US)",
volume = "2",
pages = "343--366",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Antiplatelet therapy

T2 - Current strategies and future trends

AU - Tantry, Udaya S.

AU - Etherington, Amena

AU - Bliden, Kevin P.

AU - Gurbel, Paul A.

PY - 2006/5

Y1 - 2006/5

N2 - Pharmacological management of thrombotic complications is strongly influenced by antiplatelet treatment strategies. Recent clinical trials have clearly indicated that current antiplatelet strategies may not inhibit recurrent thrombotic events in selected patients and improvement is necessary. Recently, there has been a gradual modification in the guidelines for clopidogrel dosing. In addition, newly developed P2Y12 receptor inhibitors and thrombin inhibitors are undergoing Phase II and III clinical trials. Moreover, research related to novel agents that interfere with other steps in coagulation and platelet adhesion, and platelet thromboxane and thrombin receptor blockers, show promise. An important future step will probably be the development of personalized therapy based on defining the individual patient's propensity for thrombosis through investigation of platelet-thrombin-fibrin interactions. Such an approach will enhance the targeting of specific therapy based on the pathophysiology of the individual patient.

AB - Pharmacological management of thrombotic complications is strongly influenced by antiplatelet treatment strategies. Recent clinical trials have clearly indicated that current antiplatelet strategies may not inhibit recurrent thrombotic events in selected patients and improvement is necessary. Recently, there has been a gradual modification in the guidelines for clopidogrel dosing. In addition, newly developed P2Y12 receptor inhibitors and thrombin inhibitors are undergoing Phase II and III clinical trials. Moreover, research related to novel agents that interfere with other steps in coagulation and platelet adhesion, and platelet thromboxane and thrombin receptor blockers, show promise. An important future step will probably be the development of personalized therapy based on defining the individual patient's propensity for thrombosis through investigation of platelet-thrombin-fibrin interactions. Such an approach will enhance the targeting of specific therapy based on the pathophysiology of the individual patient.

KW - Antiplatelet agents

KW - Aspirin

KW - GP IIb/IIIa inhibitors

KW - P2Y receptor blockers

KW - Platelet-thrombin-fibrin interaction

KW - Thrombin inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33646568098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646568098&partnerID=8YFLogxK

U2 - 10.2217/14796678.2.3.343

DO - 10.2217/14796678.2.3.343

M3 - Article

C2 - 19804092

AN - SCOPUS:33646568098

VL - 2

SP - 343

EP - 366

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 3

ER -